Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China

OBJECTIVE: The purpose of this study was to estimate the cost-effectiveness of sugemalimab plus chemotherapy (SC) vs. placebo plus chemotherapy (PC), as the first-line treatment for patients with non-small cell lung cancer (NSCLC) in China. MATERIAL AND METHODS: A three-state Markov model with a cyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wei, Wan, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670176/
https://www.ncbi.nlm.nih.gov/pubmed/36408023
http://dx.doi.org/10.3389/fpubh.2022.1015702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670176/
https://www.ncbi.nlm.nih.gov/pubmed/36408023
http://dx.doi.org/10.3389/fpubh.2022.1015702

Ejemplares similares